Research programme: emt protein-tyrosine kinase inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: emt protein-tyrosine kinase inhibitors - Bristol-Myers Squibb

Alternative Names: BMS 285047; BMS 431051; BMS 509744

Latest Information Update: 21 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Small molecules; Thiazoles
  • Mechanism of Action Emt protein-tyrosine kinase inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Immunosuppression

Most Recent Events

  • 13 Sep 2004 Data presented at the 228th National Meeting of the American Chemical Society (228th-ACS-2004) have been added to the pharmacokinetics and Immunological Disorders pharmacodynamics section
  • 02 Apr 2003 Preclinical trials in Immunosuppression in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top